APP-based neuroprotective strategies.
While much of the focus on Alzheimer's disease therapeutics has been directed at beta-amyloid peptide or at cholinergic synaptic transmission, recent data suggest that targeting signal transduction by the amyloid precursor protein (APP) itself may be an alternative approach with significant potential [1]. Here we discuss the possibility that APP-mediated signal transduction, downstream from amyloid-beta peptide production itself, may be an appropriate therapeutic target in Alzheimer's disease.
Bredesen
Dale E
DE
Buck Institute for Age Research and University of California, San Francisco, USA. dbredesen@buckinstitute.org
Rabizadeh
Shahrooz
S
D000544:Alzheimer Disease / Q000188:drug therapy*; D016564:Amyloid beta-Protein Precursor / Q000187:drug effects* / Q000378:metabolism*; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D051379:Mice; D015398:Signal Transduction / Q000187:drug effects
D016564:Amyloid beta-Protein Precursor; D014150:Antipsychotic Agents